10:18 AM EDT, 06/27/2024 (MT Newswires) -- KalVista Pharmaceuticals ( KALV ) said Thursday it has initiated a clinical trial of sebetralstat in hereditary angioedema patients.

The study will enroll about 24 children aged two to 11 in seven countries in North America, Europe and Asia, KalVista said.

The company said the trial will collect safety, pharmacokinetic and efficacy data for up to one year and will feature an oral disintegrating tablet formulation of sebetralstat.

Price: 11.52, Change: +0.21, Percent Change: +1.86